CINCV T
Overview:
Cincv-T is a dual-action antihypertensive formulation combining Clinidipine (10 mg) and Telmisartan (40 mg) for effective blood pressure control, vascular protection, and improved cardiovascular outcomes. This combination provides synergistic benefits by targeting both the renin-angiotensin system and calcium channels, ensuring superior blood pressure regulation with minimal side effects.
- Class
- Dosage
- Indications
- Mechanism of action
Antihypertensive
Adults: 1 tablet daily or as prescribed by a physician
- Essential Hypertension – Effective BP control with dual-action therapy.
- Cardiovascular Protection – Reduces the risk of heart failure, stroke, and renal impairment.
- Patients with High Vascular Resistance – Ensures better arterial compliance and protection.
Cincv-T works through a dual pathway to optimize blood pressure control:
Clinidipine (10 mg) is a 4th-generation dihydropyridine calcium channel blocker (CCB) that blocks L-type and N-type calcium channels, reducing peripheral resistance while preventing reflex tachycardia. It also minimizes pressure-induced kidney damage.
Telmisartan (40 mg) is an angiotensin II receptor blocker (ARB) that inhibits the renin-angiotensin system (RAS), preventing vasoconstriction and reducing vascular resistance, leading to sustained blood pressure reduction.
Together, Clinidipine and Telmisartan provide superior antihypertensive effects, improved arterial flexibility, and kidney protection, reducing the risk of cardiovascular complications.
